Mineralocorticoid Receptor Antagonists, Blood Pressure, and Drug Discontinuation

descriptionPublicationkeyboard_double_arrow_right Article 01 Jul 2020 English Publisher:Elsevier BVJournal:JACC: Heart Failure, volume 8, page 595 (issn: 2213-1779,

Copyright policy )

Authors: Pedro, Marques; Joana Tender, Vieira; Luís, Flores; Ana, Ribeiro; Ana, Faceira;

doi: 10.1016/j.jchf.2020.04.011

pmid: 32616169

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Drug Discontinuation

- Summary
- Subjects
- Metrics

Abstract

Serenelli et al. ([1][1]) investigated the effects of mineralocorticoid receptor antagonists (MRAs) on systolic blood pressure (SBP) and outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Data from 2 randomized clinical trials using MRAs were compared with those with

Keywords

Heart Failure, Hypertension, Humans, Blood Pressure, Stroke Volume, Mineralocorticoid Receptor Antagonists

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average